The advent of tyrosine kinase inhibitors (TKIs), which competitively disrupt enzyme activity through binding on the adenosine triphosphate (ATP)-binding site of BCR::ABL1, has substantially improved outcome of CML patients and is now standard of care. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.